268 related articles for article (PubMed ID: 23832575)
1. Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis.
Inoue K; Hamano T; Nango N; Matsui I; Tomida K; Mikami S; Fujii N; Nakano C; Obi Y; Shimomura A; Kusunoki Y; Rakugi H; Isaka Y; Tsubakihara Y
J Bone Miner Metab; 2014 May; 32(3):271-80. PubMed ID: 23832575
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros.
Rossini M; Orsolini G; Viapiana O; Adami S; Gatti D
Endocrine; 2015 Aug; 49(3):620-7. PubMed ID: 25649760
[TBL] [Abstract][Full Text] [Related]
4. [Glucocorticoid and Bone. Efficacy of active vitamin D on glucocorticoid-induced osteoporosis].
Miki T; Okamoto K
Clin Calcium; 2014 Sep; 24(9):1387-92. PubMed ID: 25177012
[TBL] [Abstract][Full Text] [Related]
5. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
6. [Guidelines for the treatment of glucocorticoid-induced osteoporosis and their future problems].
Soen S
Clin Calcium; 2006 Nov; 16(11):1788-96. PubMed ID: 17079844
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates and glucocorticoid-induced osteoporosis: cons.
Lems WF; Saag K
Endocrine; 2015 Aug; 49(3):628-34. PubMed ID: 26041376
[TBL] [Abstract][Full Text] [Related]
8. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis.
Boling EP
Clin Ther; 2004 Jan; 26(1):1-14. PubMed ID: 14996513
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects.
Mazziotti G; Giustina A; Canalis E; Bilezikian JP
Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1404-12. PubMed ID: 18209880
[TBL] [Abstract][Full Text] [Related]
10. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.
Glüer CC; Marin F; Ringe JD; Hawkins F; Möricke R; Papaioannu N; Farahmand P; Minisola S; Martínez G; Nolla JM; Niedhart C; Guañabens N; Nuti R; Martín-Mola E; Thomasius F; Kapetanos G; Peña J; Graeff C; Petto H; Sanz B; Reisinger A; Zysset PK
J Bone Miner Res; 2013 Jun; 28(6):1355-68. PubMed ID: 23322362
[TBL] [Abstract][Full Text] [Related]
12. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
Tanaka I
Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid-induced osteoporosis.
Silverman SL; Lane NE
Curr Osteoporos Rep; 2009 Mar; 7(1):23-6. PubMed ID: 19239826
[TBL] [Abstract][Full Text] [Related]
14. Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology.
Wall E; Walker-Bone K
QJM; 2008 Apr; 101(4):317-23. PubMed ID: 18270228
[TBL] [Abstract][Full Text] [Related]
15. [Active vitamin D3 therapy for gulucocorticoid-induced osteoporosis].
Nakayama H
Clin Calcium; 2006 Jul; 16(7):1201-7. PubMed ID: 16816482
[TBL] [Abstract][Full Text] [Related]
16. A survey of steroid-related osteoporosis diagnosis, prevention and treatment practices of pediatric rheumatologists in North America.
Soybilgic A; Tesher M; Wagner-Weiner L; Onel KB
Pediatr Rheumatol Online J; 2014; 12():24. PubMed ID: 25053923
[TBL] [Abstract][Full Text] [Related]
17. [Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment].
Di Munno O; Delle Sedie A
Reumatismo; 2006; 58(1):11-21. PubMed ID: 16639483
[TBL] [Abstract][Full Text] [Related]
18. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
[TBL] [Abstract][Full Text] [Related]
19. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
[TBL] [Abstract][Full Text] [Related]
20. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
